MCID: LTR001
MIFTS: 60

Lateral Sclerosis

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 74
Primary Lateral Sclerosis 12 77 54 55 56
Adult-Onset Primary Lateral Sclerosis 12 54
Motor Neuron Disease 45 74
Adult-Onset Pls 54

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD9CM 36 335.24
MeSH 45 D016472
NCIt 51 C129933
SNOMED-CT 69 81211007
ICD10 34 G12.23

Summaries for Lateral Sclerosis

NIH Rare Diseases : 54 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, adult, 1 and amyotrophic lateral sclerosis 2, juvenile, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (Alsin Rho Guanine Nucleotide Exchange Factor ALS2), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : 77 Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, adult, 1 34.6 ALS2 SOD1
2 amyotrophic lateral sclerosis 2, juvenile 34.6 ALS2 SOD1
3 amyotrophic lateral sclerosis 4, juvenile 34.5 ALS2 SETX
4 amyotrophic lateral sclerosis type 6 34.5 ALS2 FUS SETX TARDBP
5 amyotrophic lateral sclerosis 16, juvenile 34.4 ALS2 SIGMAR1 SOD1
6 amyotrophic lateral sclerosis 18 34.4 C9orf72 FUS SOD1 TARDBP
7 amyotrophic lateral sclerosis 20 34.3 ALS2 HNRNPA1
8 juvenile amyotrophic lateral sclerosis 34.3 ALS2 FUS SETX SIGMAR1
9 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.3 C9orf72 CHCHD10 FUS TARDBP UBQLN2 VCP
10 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.1 ALS2 ANG FIG4 FUS SETX TARDBP
11 amyotrophic lateral sclerosis 11 34.1 ALS2 ANG FIG4 FUS SETX TARDBP
12 amyotrophic lateral sclerosis 9 34.1 ALS2 ANG FIG4 FUS SETX TARDBP
13 amyotrophic lateral sclerosis type 14 34.0 FUS TARDBP UBQLN2 VAPB VCP
14 amyotrophic lateral sclerosis 21 34.0 C9orf72 FUS SETX SOD1 TARDBP VAPB
15 amyotrophic lateral sclerosis 7 34.0 ALS2 ANG FIG4 FUS SETX TARDBP
16 frontotemporal dementia 32.8 C9orf72 CHCHD10 FUS HNRNPA1 NEFH SOD1
17 progressive muscular atrophy 32.5 C9orf72 TARDBP
18 distal hereditary motor neuropathies 32.1 DCTN1 SETX
19 perry syndrome 32.0 C9orf72 DCTN1 TARDBP
20 motor neuron disease 31.8 ALS2 C9orf72 CHCHD10 DCTN1 FUS NEFH
21 amyotrophic lateral sclerosis 1 31.6 ALS2 ANG C9orf72 CHCHD10 DCTN1 FIG4
22 spinal muscular atrophy 30.7 CHCHD10 HNRNPA1 SIGMAR1 VAPB
23 dementia 30.6 C9orf72 CHCHD10 FUS HNRNPA1 TARDBP TRPM7
24 progressive non-fluent aphasia 30.3 C9orf72 VCP
25 brown-vialetto-van laere syndrome 30.2 ALS2 C9orf72 SOD1 TARDBP UBQLN2
26 charcot-marie-tooth disease 30.2 DCTN1 FIG4 NEFH SETX VCP
27 behavioral variant of frontotemporal dementia 30.1 C9orf72 VCP
28 semantic dementia 30.0 C9orf72 TARDBP
29 primary lateral sclerosis, juvenile 12.7
30 madras motor neuron disease 12.7
31 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 12.7
32 amyotrophic lateral sclerosis 8 12.7
33 amyotrophic lateral sclerosis 19 12.6
34 amyotrophic lateral sclerosis 17 12.6
35 amyotrophic lateral sclerosis 6 with or without frontotemporal dementia 12.6
36 amyotrophic lateral sclerosis 14 with or without frontotemporal dementia 12.6
37 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.6
38 amyotrophic lateral sclerosis 12 12.5
39 amyotrophic lateral sclerosis 3 12.5
40 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.5
41 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.5
42 amyotrophic lateral sclerosis 15 with or without frontotemporal dementia 12.5
43 amyotrophic lateral sclerosis 23 12.5
44 amyotrophic lateral sclerosis type 5 12.5
45 amyotrophic lateral sclerosis 25 12.5
46 amyotrophic lateral sclerosis 22 with or without frontotemporal dementia 12.5
47 amyotrophic lateral sclerosis 24 12.5
48 amyotrophic lateral sclerosis 5, juvenile 12.5
49 amyotrophic lateral sclerosis, juvenile, with dementia 12.4
50 amyotrophic lateral sclerosis type 15 12.4

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, myoclonus, hemiplegia, muscular fasciculation

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 ANG FUS HNRNPA1 RNF19A SETX SOD1

MGI Mouse Phenotypes related to Lateral Sclerosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ALS2 C9orf72 DCTN1 FIG4 NEFH RNF19A
2 cellular MP:0005384 9.9 C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3 muscle MP:0005369 9.5 ALS2 DCTN1 FIG4 SOD1 TARDBP VAPB
4 nervous system MP:0003631 9.4 ALS2 C9orf72 DCTN1 FIG4 NEFH PRPH

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 338)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
2
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
3
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
4 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
7 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
10 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
12 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
13 Central Nervous System Stimulants Phase 4,Phase 1
14 Cytochrome P-450 CYP3A Inducers Phase 4
15 Wakefulness-Promoting Agents Phase 4
16
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
17
Iron Approved, Experimental Phase 2, Phase 3,Not Applicable 7439-89-6, 15438-31-0 23925 27284
18
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
19
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3 13422-55-4
20
Edaravone Approved, Investigational Phase 3,Phase 2 89-25-8 70335
21
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
22
Dopamine Approved Phase 2, Phase 3,Phase 3,Phase 1 62-31-7, 51-61-6 681
23
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 15589840
24
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6 32051
25
Mecasermin Approved, Investigational Phase 3 68562-41-4
26
Sargramostim Approved, Investigational Phase 2, Phase 3,Not Applicable 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
28
Pramipexole Approved, Investigational Phase 3,Phase 1,Phase 2 104632-26-0 119570 59868
29
Minocycline Approved, Investigational Phase 3,Phase 2 10118-90-8 5281021
30
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
31
Valproic Acid Approved, Investigational Phase 3,Phase 2 99-66-1 3121
32
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
33
Acetylcholine Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 51-84-3 187
34
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 93-14-1 3516
35
Dextromethorphan Approved Phase 3,Phase 2,Phase 1 125-71-3 5362449 5360696
36
Quinidine Approved, Investigational Phase 3,Phase 2,Phase 1 56-54-2 441074
37
Citalopram Approved Phase 3 59729-33-8 2771
38
Sodium Citrate Approved, Investigational Phase 3,Phase 2 68-04-2
39
Deferiprone Approved Phase 2, Phase 3,Not Applicable 30652-11-0 2972
40
Creatine Approved, Investigational, Nutraceutical Phase 3,Phase 2 57-00-1 586
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 59-30-3 6037
42
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
43
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
44
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3,Phase 2 303-98-0 5281915
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
46
Cobalamin Experimental Phase 2, Phase 3,Phase 3 13408-78-1 6857388
47 Tocotrienol Investigational Phase 3 6829-55-6
48 Nabiximols Investigational Phase 2, Phase 3 56575-23-6
49
Taurochenodeoxycholic acid Experimental Phase 3,Phase 2 516-35-8 387316
50
Tauroursodeoxycholic acid Experimental, Investigational Phase 3,Phase 2 14605-22-2 12443252

Interventional clinical trials:

(show top 50) (show all 515)
# Name Status NCT ID Phase Drugs
1 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
2 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients Completed NCT00614926 Phase 4 Modafinil;Placebo
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
7 Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
8 Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
9 Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
10 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
11 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
12 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
13 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
14 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
15 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
16 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
17 The Effect of GCSF in the Treatment of ALS Patients Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
18 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
19 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
20 Phase 3 Study of Dexpramipexole in ALS Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
21 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
22 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
23 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
24 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
25 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS Completed NCT00372879 Phase 3
26 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Completed NCT00136110 Phase 3 Sodium Valproate
27 Clinical Trial Ceftriaxone in Subjects With ALS Completed NCT00349622 Phase 3 ceftriaxone
28 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
29 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS Completed NCT00868166 Phase 3 Olesoxime;Placebo Comparator;Riluzole
30 A Study for Patients Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
31 Safety Extension Study of TRO19622 in ALS Completed NCT01285583 Phase 2, Phase 3 TRO19622
32 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Completed NCT02496767 Phase 3 tirasemtiv;Placebo tablets;Riluzole 50 MG
33 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3 AVP-923
34 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
35 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
36 Escitalopram (Lexapro) for Depression MS or ALS Completed NCT00965497 Phase 3 escitalopram
37 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
38 Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Completed NCT01257828 Phase 3 riluzole;Placebo medication
39 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
40 Arimoclomol in Amyotropic Lateral Sclerosis Recruiting NCT03491462 Phase 3 Arimoclomol;Placebo oral capsule
41 Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Recruiting NCT03690791 Phase 3 CannTrust CBD Oil (capsule);Placebo (capsule)
42 Clinical Trial of Ultra-high Dose Methylcobalamin for ALS Recruiting NCT03548311 Phase 3 methylcobalamin;saline solution
43 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT02623699 Phase 3 BIIB067
44 Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Recruiting NCT03800524 Phase 3 Tauroursodeoxycholic acid (TUDCA);Placebo
45 Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients Recruiting NCT03280056 Phase 3
46 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS Recruiting NCT03505021 Phase 3 Levosimendan;Placebo for levosimendan
47 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Recruiting NCT03347344 Phase 3 Riluzole;Placebo
48 Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) Active, not recruiting NCT03272802 Phase 2, Phase 3 Edaravone;Riluzole
49 Long-Term Evaluation of BIIB067 Enrolling by invitation NCT03070119 Phase 3 BIIB067
50 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

42
Brain, Spinal Cord, Bone, Testes, Cortex, Skeletal Muscle, Bone Marrow

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 5305)
# Title Authors Year
1
Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. ( 30740050 )
2019
2
Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis. ( 30565851 )
2019
3
Assessing Anxiety and its correlates in Amyotrophic Lateral Sclerosis: the State-Trait Anxiety Inventory. ( 30897219 )
2019
4
Hereditary primary lateral sclerosis and progressive nonfluent aphasia. ( 30834979 )
2019
5
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. ( 30859373 )
2019
6
A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: A rare co-occurrence of autism spectrum disorder and tremor. ( 30684766 )
2019
7
Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. ( 30911572 )
2019
8
HR23B pathology preferentially co-localizes with p62, pTDP-43 and poly-GA in C9ORF72-linked frontotemporal dementia and amyotrophic lateral sclerosis. ( 30867060 )
2019
9
Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. ( 30763568 )
2019
10
Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. ( 30791515 )
2019
11
Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )
2019
12
Depression and risk of Cognitive Dysfunctions in Amyotrophic Lateral Sclerosis. ( 30712314 )
2019
13
A case of amyotrophic lateral sclerosis which was diagnosed with progressive dysphagia and muscle atrophy. ( 30631656 )
2019
14
GABAB receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis. ( 30871492 )
2019
15
Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS. ( 30635486 )
2019
16
VAPB depletion alters neuritogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked ALS. ( 30745341 )
2019
17
Response to Letter to the Editor: "Amyotrophic lateral sclerosis and exposure to diesel exhaust in a Danish cohort". ( 30753256 )
2019
18
High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. ( 30760645 )
2019
19
Muscle secretion of toxic factors, regulated by miR126-5p, facilitates motor neuron degeneration in amyotrophic lateral sclerosis. ( 30762002 )
2019
20
Corrigendum to "Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis" [Brain Research Bulletin 140 (2018) 318-333]. ( 30770039 )
2019
21
Contact Sports as a Risk Factor for Amyotrophic Lateral Sclerosis: A Systematic Review. ( 30775214 )
2019
22
Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30782181 )
2019
23
Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. ( 30784318 )
2019
24
TDP-43: A KEY THERAPEUTIC TARGET BEYOND AMYOTROPHIC LATERAL SCLEROSIS. ( 30785719 )
2019
25
Smoking and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. ( 30786056 )
2019
26
Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis. ( 30789031 )
2019
27
Regional dynamics of the resting brain in amyotrophic lateral sclerosis using fALFF and ReHo analyses. ( 30793923 )
2019
28
Tract integrity in amyotrophic lateral sclerosis: 6-month evaluation using MR diffusion tensor imaging. ( 30795741 )
2019
29
Excitability in somatosensory cortex correlates with motoric impairment in amyotrophic lateral sclerosis. ( 30798637 )
2019
30
Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807321 )
2019
31
Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807353 )
2019
32
Edaravone for the treatment of amyotrophic lateral sclerosis. ( 30810406 )
2019
33
Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30811816 )
2019
34
Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. ( 30811981 )
2019
35
A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. ( 30814647 )
2019
36
Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. ( 30816241 )
2019
37
Psychological flexibility and attitudes toward evidence-based interventions by amyotrophic lateral sclerosis patients. ( 30828499 )
2019
38
Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. ( 30837838 )
2019
39
Information-domain method for the quantification of the complexity of the sympathetic baroreflex regulation in healthy subjects and amyotrophic lateral sclerosis patients. ( 30840931 )
2019
40
Amyotrophic Lateral Sclerosis: The Assessment of Inspiratory Muscle Failure. ( 30846202 )
2019
41
Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. ( 30846540 )
2019
42
A near miss: Autonomic dysfunction in a 2% total burn surface area burn patient with ventilator-dependent amyotrophic lateral sclerosis. ( 30847184 )
2019
43
Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations. ( 30847648 )
2019
44
Impaired short and long latency afferent inhibition in ALS. ( 30847934 )
2019
45
Androgen receptor antagonism accelerates disease onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30849180 )
2019
46
Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. ( 30850472 )
2019
47
Carboxyl-terminal modulator protein regulates Akt signaling during skeletal muscle atrophy in vitro and a mouse model of amyotrophic lateral sclerosis. ( 30850672 )
2019
48
Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. ( 30855701 )
2019
49
ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis. ( 30861116 )
2019
50
Searching for Bacteria in Neural Tissue From Amyotrophic Lateral Sclerosis. ( 30863279 )
2019

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 DCTN1 NEFH SIGMAR1 SOD1 TARDBP
2
Show member pathways
11.37 DCTN1 NEFH PRPH
3
Show member pathways
10.98 ALS2 NEFH PRPH SOD1

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.72 ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2 neuronal cell body GO:0043025 9.55 ALS2 ANG DCTN1 FUS SOD1
3 myelin sheath GO:0043209 9.54 NEFH SOD1 VCP
4 lipid droplet GO:0005811 9.43 FIG4 SIGMAR1 VCP
5 axon GO:0030424 9.35 ALS2 C9orf72 DCTN1 NEFH SETX
6 growth cone GO:0030426 9.02 ALS2 ANG C9orf72 SETX SIGMAR1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.33 ALS2 FIG4 SOD1
2 regulation of autophagosome assembly GO:2000785 8.96 C9orf72 UBQLN2
3 neurofilament cytoskeleton organization GO:0060052 8.62 NEFH SOD1

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dynein complex binding GO:0070840 8.62 DCTN1 NEFH

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....